All, I'm trying to further my knowledge and understand PAT-SM6's place in the market.
Just reading up a little on Daratumumab after that article mentions it. These are the results of the Phase 1/2 study for Daratumumab:
"To date, the study has enrolled 29 relapsed or refractory myeloma patients."
"At the most recent follow-up, researchers found that 24 percent of patients have achieved a partial response. An additional 14 percent of patients have achieved a minimal response, and 24 percent of patients have stable disease."
So based on that I assume their results were significantly better than PABs?
On the upside we don't seem to have any negative side effects and have a very low toxicity profile. Does this mean the most likely (or only) way forward for PAT-SM6 is in combination with another treatment? From the results it seems PAT-SM6 may make other drugs more effective but would not be a primary/solitary treatment option like others?
- Forums
- ASX - By Stock
- PAB
- should there have been an announcement today?
should there have been an announcement today? , page-4
-
- There are more pages in this discussion • 65 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAB (ASX) to my watchlist
|
|||||
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.34M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 915838 | 0.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.7¢ | 1050244 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 915838 | 0.006 |
16 | 8665158 | 0.005 |
11 | 6064000 | 0.004 |
7 | 6399016 | 0.003 |
1 | 2520000 | 0.002 |
Price($) | Vol. | No. |
---|---|---|
0.007 | 1050244 | 4 |
0.008 | 2781393 | 7 |
0.009 | 80000 | 1 |
0.010 | 1396000 | 6 |
0.012 | 292407 | 2 |
Last trade - 16.12pm 21/08/2024 (20 minute delay) ? |
Featured News
PAB (ASX) Chart |
Day chart unavailable